Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 9:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo group Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Blood Flow Restriction and Creatine Supplementation in Women

NCT05877417
View directory record Official record
Conditions
Physical Inactivity
Interventions
Creatine Monohydrate, Blood Flow Restriction, Exercise
Dietary Supplement · Device · Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Sep 23, 2026, 9:14 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

NCT00631917
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Placebo to Ramipril, Placebo to Aliskiren
Drug · Other
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 23, 2026, 9:14 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis

NCT04160091
View directory record Official record
Conditions
Osteoarthritis of the Shoulder, Adhesive Capsulitis
Interventions
FX006, Normal Saline
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
35 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
27
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 23, 2026, 9:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Quercetin's Effect on Bone Health and Inflammatory Markers

NCT05371340
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Quercetin (500 mg), Placebo (500 mg)
Dietary Supplement · Other
Lead sponsor
Kennesaw State University
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kennesaw, Georgia
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Sep 23, 2026, 9:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

AZD8108 SAD/MAD in Healthy Volunteers

NCT02248818
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD8108, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 23, 2026, 9:14 AM EDT
Terminated Phase 1Phase 2 Interventional

Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease

NCT04519697
View directory record Official record
Conditions
Rectovaginal Fistula, Crohn Disease, Crohn Disease of Vulva, Rectolabial; Fistula
Interventions
Mesenchymal Stem Cells, Placebo
Drug · Other
Lead sponsor
Anthony Lembo
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 23, 2026, 9:14 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

NCT00808210
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Infliximab, Methotrexate, Methylprednisolone, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 23, 2026, 9:14 AM EDT
Completed Phase 4 Interventional Results available

Adolescent Fibromyalgia Study

NCT01020474
View directory record Official record
Conditions
Fibromyalgia
Interventions
placebo, pregabalin (Lyrica)
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
30
States / cities
Los Angeles, California • Santa Ana, California • Delray Beach, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 23, 2026, 9:14 AM EDT
Active, not recruiting Not applicable Interventional

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)

NCT04065490
View directory record Official record
Conditions
Dry Age-related Macular Degeneration
Interventions
Valeda PBM treatment, Valeda Sham treatment
Device
Lead sponsor
LumiThera, Inc.
Industry
Eligibility
50 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Beverly Hills, California • Palo Alto, California • Altamonte Springs, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 23, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain

NCT01280591
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111), Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111), Naproxen sodium 440 mg (BAYH6689), DPH 50 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 45 Years
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Austin, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 23, 2026, 9:14 AM EDT
Completed Phase 2 Interventional

A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)

NCT00275197
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Sertraline and Elzasonan Combination, Sertraline, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Beverly Hills, California • Norwich, Connecticut • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2008 · Synced Sep 23, 2026, 9:14 AM EDT
Terminated Not applicable Interventional Results available

Lidocaine and Ketamine in Abdominal Surgery

NCT00721110
View directory record Official record
Conditions
Abdominal Hysterectomy (& Wertheim)
Interventions
Lidocaine, Placebo, Ketamine, Ketamine + Lidocaine
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Mayfield Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 23, 2026, 9:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers

NCT00000774
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
rgp120/HIV-1MN, rgp120/HIV-1 SF-2, Placebo version of rgp120/HIV-1MN, Placebo version of rgp120/HIV-1SF2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 3 Days
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
36
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 23, 2026, 9:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Consumption of Post-harvest UV-B Treated Mushrooms on Vitamin D Status of Healthy Adults

NCT01443897
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
1,000 IU vitamin D2, placebo capsule, mushrooms, UVB-treated mushrooms, 400 IU vitamin D2, UVB-treated mushrooms, 1,000 IU vitamin D2
Dietary Supplement · Other
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
20 Years to 59 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2011 · Synced Sep 23, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Results available

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

NCT02968810
View directory record Official record
Conditions
Cirrhosis, Hepatocellular Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration, Questionnaire Administration, Simvastatin
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 23, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Results available

An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects

NCT03084718
View directory record Official record
Conditions
Asthma
Interventions
CHF 718 pMDI, Placebo pMDI, Beclomethasone Dipropionate (BDP)
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 75 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
134
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 23, 2026, 9:14 AM EDT
Withdrawn Phase 2 Interventional

Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital

NCT06834997
View directory record Official record
Conditions
Endometriosis, Endometriosis Related Pain, Endometriosis, Pain
Interventions
Dronabinol Capsules, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Hosuton, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 23, 2026, 9:14 AM EDT
Completed Phase 4 Interventional Results available

Lansoprazole to Treat Children With Asthma

NCT00442013
View directory record Official record
Conditions
Asthma
Interventions
Lansoprazole, Matching placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Years to 17 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Sep 23, 2026, 9:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

NCT00376090
View directory record Official record
Conditions
HIV Infections
Interventions
MVA-CMDR, Placebo
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Sep 23, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Results available

Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis

NCT03863574
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis
Interventions
Saroglitazar Magnesium 2mg, Saroglitazar Magnesium 4mg, Placebos
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Jackson, Mississippi • Germantown, Tennessee • Hermitage, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 23, 2026, 9:14 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

RCT Comparing ESWT With PRP for Plantar Fasciitis in High Demand Cohort

NCT02668510
View directory record Official record
Conditions
Fasciitis, Plantar
Interventions
platelet rich plasma, Normal saline
Biological · Drug
Lead sponsor
Edna Rath
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 23, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Results available

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

NCT04922554
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
Interventions
Omadacycline Oral Tablet, Placebo
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Stanford, California • Washington D.C., District of Columbia • Clearwater, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 23, 2026, 9:14 AM EDT
Completed Phase 4 Interventional Results available

Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients

NCT03055494
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Secukinumab, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
15
States / cities
Hot Springs, Arkansas • Los Angeles, California • Santa Ana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 23, 2026, 9:14 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Lu AG06479 in Healthy Young Men

NCT04473651
View directory record Official record
Conditions
Healthy
Interventions
Lu AG06479, Placebos
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 23, 2026, 9:14 AM EDT